HC Wainwright Has Strong Forecast for IPSEN FY2027 Earnings

IPSEN (OTCMKTS:IPSEY) – Equities research analysts at HC Wainwright raised their FY2027 earnings estimates for shares of IPSEN in a report issued on Friday, July 31st. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of $4.20 for the year, up from their prior estimate of $4.05. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for IPSEN’s current full-year earnings is $3.71 per share.

Several other research analysts have also issued reports on IPSEY. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of IPSEN in a research report on Thursday, May 14th. Jefferies Financial Group downgraded IPSEN to an “underperform” rating in a report on Sunday. Finally, Zacks Research upgraded IPSEN to a “hold” rating in a research report on Friday, May 29th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold”.

IPSEN Trading Up 1.9%

Shares of IPSEN stock opened at $45.71 on Monday. The firm’s 50-day simple moving average is $45.77 and its 200-day simple moving average is $45.67. IPSEN has a twelve month low of $30.05 and a twelve month high of $51.10.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).